Related Experiment Video
Updated: Jul 4, 2026

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
Neuregulins and cancer
Juan Carlos Montero1, Ruth Rodríguez-Barrueco, Alberto Ocaña
1Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain.
Abstract:
The neuregulins represent the largest subclass of polypeptide factors of the epidermal growth factor family of ligands. These molecules are synthesized as membrane-bound, biologically active growth factors that act by binding to the HER/ErbB receptor tyrosine kinases. Preclinical data have indicated that increased expression and function of neuregulins may provoke cancer. Furthermore, neuregulin expression has been detected in several neoplasias, and their presence may correlate with response to treatments that target the HER receptors such as trastuzumab. In addition, the neuregulins have also been implicated in resistance to anti-HER therapies. Therefore, targeting of the neuregulins may be helpful in neoplastic diseases in which these polypeptide factors contribute to tumor generation and/or maintenance.
Insights
Neuregulins, a type of epidermal growth factor, may promote cancer by activating HER/ErbB receptors. Targeting neuregulins could be a strategy for treating cancers where they drive tumor growth.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Neuregulins are the largest subgroup of epidermal growth factor (EGF) family ligands.
- They function as membrane-bound growth factors that bind to HER/ErbB receptor tyrosine kinases.
- Neuregulins are implicated in cancer development and progression.
Purpose of the Study:
- To explore the role of neuregulins in cancer.
- To investigate the potential of targeting neuregulins in cancer therapy.
Main Methods:
- Review of preclinical data on neuregulin expression and function in cancer.
- Analysis of neuregulin presence in various neoplasias.
- Examination of neuregulin's correlation with response to HER-targeted therapies.
Main Results:
- Increased neuregulin expression and function may provoke cancer.
- Neuregulin expression is detected in several types of cancer.
- Neuregulin presence correlates with response to HER-targeted treatments like trastuzumab.
- Neuregulins are also implicated in resistance to anti-HER therapies.
Conclusions:
- Neuregulins play a significant role in cancer generation and maintenance.
- Targeting neuregulins may offer a therapeutic strategy for neoplastic diseases.
- Understanding neuregulin's role is crucial for optimizing HER-targeted cancer treatments.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Mitogens and the Cell Cycle
Negative Regulator Molecules